Design engineers in the biotechnology sector must navigate a complex landscape where stakeholder expectations escalate alongside shortened development timelines. Continuous improvement is a targeted approach to enhancing processes, products and outcomes. By integrating these practices, forward-thinking organizations can bridge the gap between ambitious concepts and real-world results.
Leading companies achieve measurable results through logistics optimization, artificial intelligence and digital twins. Additionally by layering powerful problem-solving frameworks like lean and kaizen into their daily workflows, these innovators are empowering design engineers to deliver exceptional results. What strategies are redefining efficiency and precision in the lab and beyond?
Building an Integrated Technology Portfolio for Operational Excellence
Integrating advanced tools and platforms is only half the battle. To lead in a competitive market, biotech organizations need to foster a culture that empowers top-tier talent that is committed to continual improvement. It’s about building a foundation where technology amplifies human potential.
The Danaher Business System (DBS) exemplifies this philosophy. Instead of relying on disconnected processes, Danaher uses DBS to unite strategy, organization, talent and culture into a cohesive system for growth that accelerates innovation across the biotech and life sciences sectors.
Through this commitment to growth, over 80% of 2023 FDA-approved cancer drugs are supported by SCIEX technology and 100% of FDA-approved cell and gene therapy drug manufacturers count on one of Danaher's Life Science companies. Their approach to continuous improvement creates a setting where design engineers lead breakthroughs and adhere to rigorous quality standards.
Optimizing the Biotech Supply Chain for Efficiency
Biotech logistics demand precision, from mastering strict regulatory compliance to carefully managing temperature-sensitive materials across global networks. Forward-thinking companies tackle these complexities head-on to safeguard product development timelines and maximize operational efficiency.
A multinational biopharma company partnered with Deloitte to address critical visibility issues that hampered its operations. Teams needed hours to manually consolidate information from disparate sources before beginning their analyses. This fragmentation limited real-time performance insights and prevented workers from finding optimization opportunities.
Creating a unified analytics platform broke down existing data silos and enabled a more seamless flow across over 20 manufacturing sites. This effort achieved an 85% reduction in the time required to retrieve and consolidate raw information from operations. The company also realized a 75% reduction in the time needed to transform that consolidated information into actionable insights at plants.
Streamline Maintenance Methods with AI
Unexpected downtime kills momentum, but Generative AI (GenAI) is rewriting the rules of the lab. By combining the predictive nature of GenAI with the proven precision of lean and kaizen workflows, teams can proactively eliminate bottlenecks before they have a chance to impact a development schedule.
For instance, McKinsey examined how biopharma companies have applied GenAI to maintenance operations. One team deployed a GenAI chatbot that gave technicians instant access to documentation, troubleshooting guides and records. It interpreted natural-language questions and delivered tailored responses in context.
Integrating GenAI led to a 5% reduction in breakdown duration, speed losses and minor stoppages. These improvements shortened execution time by 30%. The biggest impact was in corrective maintenance, where teams enjoyed up to 50% lighter workloads.
Redefining Clinical Trials With Digital Twins
Digital twins are revolutionizing clinical trials. Researchers leveraging AI simulations can identify ingredients and formulations that are most likely to produce desired results in target patient populations.
Sanofi invested in digital twin technology to streamline trial timelines. They developed proprietary models combining artificial intelligence and machine learning with quantitative systems pharmacology (QSP) to generate explainable predictions. This approach allows researchers to understand the forecasted results and determine if they make scientific sense.
By demonstrating that simulations could reproduce outcomes observed in patients, Sanofi validated the digital twin technology's accuracy, streamlining regulatory requirements. When developing a candidate targeting a rare disease, the digital twin allowed the company to present evidence to regulatory authorities without an expansive pediatric study. The ability to run clinical trials faster while maintaining scientific rigor marked a major step forward.
The company has successfully applied this methodology to multiple candidates, including Lunsekimig, an asthma drug candidate, and Xenpozyme, which treats acid sphingomyelinase deficiency. In both cases, the simulated forecasts aligned with actual results, building confidence in the reliability of digital twins.
Frequently Asked Questions About Continuous Improvement in Biotech
Here are some common questions about continuous improvement options in the biotech industry.
What role does maintenance play in product development?
Maintenance supports product development by ensuring specialized machinery operates reliably. Unexpected failures delay experiments, interrupt growth and compromise data quality during critical phases.
How do digital twins enable continuous improvement in clinical trials?
Digital twins enable researchers to simulate trial scenarios before recruiting participants. This allows them to identify optimal study designs and predict outcomes with greater accuracy. After trials conclude, teams can use simulations to answer additional questions without running new studies.
How can companies use generative AI for continuous improvement?
GenAI applications in biotech include support chatbots, documentation analysis tools and process optimization systems. They help researchers access information faster , reduce time spent on routine tasks and identify operational improvements.
Building a Future-Ready Biotech Enterprise
Excellence in biotechnology demands the bold integration of emerging technology while recognizing when proven lean methodologies or other optimization techniques make more sense. Establishing clear metrics for improvement initiatives empowers leaders to determine whether specific investments delivered the intended results.
While true innovation requires patience, the payoff is profound. Companies achieve the best outcomes by determining goals and rationale before selecting approaches. Learning from pioneers in the space and expanding or adapting those strategies can accelerate progress while reducing implementation risks.
